Ultragenyx cuts jobs as it seeks path to profit in 2027

Core Insights - Ultragenyx has successfully launched four rare disease treatments but has not yet achieved profitability, reporting a net loss of $575 million against full-year revenue of $673 million [3] - The company aims to reach profitability by 2027, although recent setbacks have altered revenue growth expectations [3] Drug Development and Regulatory Challenges - A drug co-developed with Mereo Biopharma failed a Phase 3 trial for osteogenesis imperfecta, and the gene therapy UX111 for Sanfilippo syndrome Type A was rejected by the FDA due to manufacturing concerns [4] - The FDA's rejection of UX111 has created uncertainty regarding biomarker-based approvals in rare diseases and gene therapy, impacting revenue outlook [5] Corporate Restructuring and Financial Projections - Ultragenyx plans to cut 130 jobs, representing 10% of its workforce, as part of a restructuring aimed at supporting profitability by 2027 [6] - The restructuring is expected to keep expenses flat or slightly reduced in 2026, with a projected 15% decrease in expenses by 2027 compared to 2025 [6] - The company anticipates revenue growth of 8 to 13 percent for the current year, despite analysts reducing share price targets due to longer approval timelines [6]